NMTRQ-TTG12-1

Across TCGA pan-cancer cohorts, NMTRQ-TTG12-1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of NMTRQ-TTG12-1’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where NMTRQ-TTG12-1 RNA is repressed in tumor relative to normal tissue. In most cancer types NMTRQ-TTG12-1 is over-expressed in tumor, although a few such as BRCA and KIRC show the opposite, repressed pattern.

BRCA and KIRC are the cancer types where NMTRQ-TTG12-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NMTRQ-TTG12-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	−0.092	.005	4	view →
KIRC	All	III,IV	−0.088	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

NMTRQ-TTG12-1–BRCA

Open the BRCA breakdown →